Novartis division Sandoz’s Rixathon (biosimilar rituximab) has received approval from the European Commission (EC) to treat blood cancers and immunological diseases in Europe.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Rixathon is approved for use in all indications of the reference medicine, MabThera.

Sandoz Biopharmaceuticals global head Carol Lynch said: “Today's approval of Rixathon represents a big win for patients in Europe with blood cancers or immunological diseases because it enables increased access to biologics.

“It also allows healthcare systems to redeploy resources to other areas of high need, particularly innovative therapies.

See Also:

"Today's approval of Rixathon represents a big win for patients in Europe with blood cancers or immunological diseases because it enables increased access to biologics."

“Sandoz is committed to increasing patient access to biologic medicines, and Rixathon will be one of the five major launches we plan in the next four years. We have worked with care and passion towards this approval, and now is the time when we are bringing this medicine to healthcare professional and patients in Europe.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The treatment is currently approved for non-Hodgkin lymphoma (follicular lymphoma and diffuses large B-cell lymphoma) and chronic lymphocytic leukaemia, in addition to immunological diseases such as rheumatoids arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.

The approval was based on a comprehensive development programme generating analytical, preclinical, and clinical data, including pharmacokinetic / pharmacodynamic (PK/PD) data.

The programme demonstrates the biosimilarity of Rixathon to its reference medicine MabThera in terms of safety, efficacy and quality.

Image: High-power magnification (1000 X) of a Wright's stained peripheral blood smear showing chronic lymphocytic leukaemia. Photo: courtesy of VashiDonsk at the English language Wikipedia.